Formation Bio Secures $372M to Enhance Drug Development Using AI

Formation Bio, an innovative startup leveraging AI for drug development, has successfully raised $372 million in a Series D funding round. Led by Andreessen Horowitz and supported by investors including Sanofi, Sequoia, and Thrive, this funding brings Formation Bio's total capital to over $600 million. The investment will primarily support partnership acquisitions and R&D initiatives. Formation Bio, co-founded by Benjamine Liu and Linhao Zhang in 2016, focuses on streamlining clinical trials and drug development processes. Their recent collaboration with OpenAI and Sanofi aims to advance AI-driven drug discovery, with AI models designed to enhance patient recruitment, data management, and drug efficacy predictions.